Your browser doesn't support javascript.
loading
IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.
Hack, Stephen P; Spahn, Jessica; Chen, Minshan; Cheng, Ann-Lii; Kaseb, Ahmed; Kudo, Masatoshi; Lee, Han Chu; Yopp, Adam; Chow, Pierce; Qin, Shukui.
Afiliación
  • Hack SP; Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA.
  • Spahn J; Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA.
  • Chen M; Department of Hepatobiliary Surgery, Cancer Centre of Sun Yat-sen University, Guangzhou, PR China.
  • Cheng AL; National Taiwan University Cancer Center & National Taiwan University Hospital, Taipei, Taiwan.
  • Kaseb A; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Kudo M; Department of Gastroenterology & Hepatology, Kindai University School of Medicine, Osaka, Japan.
  • Lee HC; Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Yopp A; Department of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Chow P; Division of Surgical Oncology, National Cancer Centre, Singapore.
  • Qin S; PLA Cancer Center, People's Liberation Army (PLA) 81 Hospital, Nanjing 210016, PR China.
Future Oncol ; 16(15): 975-989, 2020 May.
Article en En | MEDLINE | ID: mdl-32352320
Hepatocellular carcinoma recurs in 70-80% of cases following potentially curative resection or ablation and the immune component of the liver microenvironment plays a key role in recurrence. Many immunosuppressive mechanisms implicated in HCC recurrence are modulated by VEGF and/or immune checkpoints such as PD-L1. Atezolizumab (PD-L1 inhibitor) plus bevacizumab (VEGF inhibitor) has been shown to significantly improve overall survival, progression-free survival and overall response rate in unresectable HCC. Dual PD-L1/VEGF blockade may be effective in reducing HCC recurrence by creating a more immune-favorable microenvironment. We describe the rationale and design of IMbrave 050 (NCT04102098), a randomized, open-label, Phase III study comparing atezolizumab plus bevacizumab versus active surveillance in HCC patients at high-risk of recurrence following curative resection or ablation. The primary end point is recurrence-free survival. Clinical Trial Registration: NCT04102098.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: Future Oncol Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: Future Oncol Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido